# Globus Medical, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Globus Medical, Inc). ## Overview Globus Medical is a U.S.-based medical device company focused on musculoskeletal care, with products used in spine, orthopedic trauma, hip, knee, extremity and neurosurgical procedures. It combines implantable devices, biologics, surgical instruments and enabling technologies such as robotics and navigation to help surgeons perform procedures more efficiently and reproducibly. ## Products & services • Implantable devices and disposables for musculoskeletal procedures • Surgical instruments, implant sets and field-based equipment • Enabling Technologies: robotics, navigation and software systems • Neuromonitoring services and spinal cord stimulation therapy • Biologics and regenerative products, including autologous systems - **Musculoskeletal Solutions** (85%) — Implantable devices, biologics, accessories, unique surgical instruments, neuromonitoring and stimulation products used in spine and orthopedic procedures. - **Enabling Technologies** (15%) — Advanced hardware, software and related technologies that improve surgical precision, workflow and reproducibility. - Implantable devices and disposables for spine and orthopedic procedures - Surgical instruments, implant sets and field-based equipment - Robotics, navigation and other Enabling Technologies systems - Neuromonitoring services and spinal cord stimulation therapy - Biologics and regenerative products, including autologous systems ## Customers Globus sells primarily to hospitals, ambulatory surgery centers and physicians that perform musculoskeletal procedures and need both implants and the supporting surgical workflow tools. Its products are bought to improve surgical outcomes, reduce procedure complexity and support surgeon preference across a broad range of spine and orthopedic cases. - **Hospitals** (primary) — Buy implant sets, instruments, biologics and enabling technologies for inpatient and outpatient musculoskeletal procedures. - **Ambulatory surgery centers** (primary) — Buy procedure-ready systems and technologies that support faster, more efficient outpatient surgery. - **Physicians and surgeons** (primary) — Influence product selection and buy or specify surgeon-preferred implants, tools and navigation systems. - **International distributors** (secondary) — Sell and support Globus products in non-U.S. markets where direct coverage is not used. - Hospitals buying implants, instruments and procedure support - Ambulatory surgery centers seeking efficient surgical workflows - Physicians and surgeons choosing surgeon-preferred systems - Health systems that want standardized, reproducible procedures - Customers needing neuromonitoring and enabling technology support ## Geography Globus is headquartered in Audubon, Pennsylvania and operates globally, with sales presence in 65 countries worldwide and direct or distributor coverage in 64 countries outside the U.S. The U.S. remains the largest market, but international growth matters because the company is still expanding its commercial footprint across Europe, the Middle East, Asia Pacific and Latin America. - **United States** (80.8%) — Based on six months ended June 30, 2025 revenue disclosure. - **International** (19.2%) — Based on six months ended June 30, 2025 revenue disclosure. - Headquartered in Audubon, Pennsylvania, United States - U.S. is the largest revenue market and sales-force focus - International sales presence spans 64 countries outside the U.S. - Operations and commercialization extend across 65 countries worldwide - Europe, Middle East, Asia Pacific and Latin America drive non-U.S. growth ## Strategy Globus is focused on expanding its U.S. sales force, deepening penetration in existing territories and broadening coverage into new geographies. It is also pursuing international expansion and selective acquisitions to add technology, clinical capability and market access, while continuing to launch new products across its musculoskeletal portfolio. - **Expand U.S. sales force and territory coverage** (short-term) — More reps and broader coverage should increase procedure adoption and deepen account penetration. - **International expansion** (medium-term) — Broader non-U.S. commercialization diversifies revenue and extends the installed base for products and technologies. - **Selective acquisitions and alliances** (medium-term) — Acquisitions can add technology, personnel and market access that accelerate growth and product breadth. - **Product innovation and launches** (short-term) — Frequent launches support surgeon adoption and help defend share in a competitive device market. - Expand the U.S. direct and distributor sales force - Increase penetration in existing musculoskeletal markets - Grow international commercialization in current and new markets - Pursue selective acquisitions and alliances - Launch differentiated products and procedures faster than peers ## Risks Globus faces execution risk from integrating acquisitions, maintaining surgeon and hospital adoption, and managing a global supply chain that depends on third-party suppliers and international operations. It also faces regulatory, reimbursement, litigation and foreign-exchange risks typical of medical device companies, with tariff policy and customer credit exposure adding pressure to margins and cash flow. - **Acquisition integration risk** [high] — The company has grown through acquisitions and may not realize expected synergies or product benefits. - **Competitive adoption risk** [high] — Revenue depends on convincing surgeons and hospitals that Globus systems are preferable to alternatives. - **Tariff and supply-chain disruption** [medium] — Tariffs or countermeasures can increase input costs and disrupt global sourcing and distribution. - **Foreign exchange and international operations** [medium] — Non-U.S. revenue and costs create translation and transaction exposure. - **Regulatory and compliance risk** [high] — Medical device marketing, manufacturing and biologics activities are subject to FDA and fraud-and-abuse rules. - Acquisitions may be harder to integrate than expected - Surgeons and hospitals may prefer competitors' products - Tariffs and supply-chain disruption can raise costs - Foreign regulatory and currency risks affect international growth - FDA, fraud-and-abuse and off-label promotion risks can create liability ## Accounting Revenue recognition depends on whether products are implanted, shipped or delivered, and whether contracts include maintenance, support or other remaining obligations. The company also has meaningful judgment in acquisition accounting, goodwill impairment testing and inventory valuation, all of which can materially affect reported earnings and balance sheet values. - **Revenue recognition timing** — Can shift revenue between quarters and affect comparability - **Goodwill and intangible impairment** — Potential non-cash impairment charges - **Acquisition accounting and bargain purchase gain** — Can create volatile non-operating gains - **Inventory and excess/obsolete reserves** — Affects cost of sales and gross margin - **Foreign currency translation** — Can move other income/expense and net income - Point-in-time revenue for implants and many musculoskeletal products - Over-time or service-period recognition for IONM and support contracts - Goodwill and intangibles require annual impairment testing - Acquisition purchase price allocations can create bargain purchase gains - Inventory reserves and obsolete stock charges affect gross margin --- *Last updated: 2026-04-28T20:10:13.264249+00:00*